Keri Medical SA appears in FDA records as the applicant for KeriFlex® MCP and PIP Finger Joint Prostheses, a Class II orthopedic device regulated as a finger joint polymer constrained prosthesis under 21 CFR 888.3230 and product code KYJ. The supplied filing collection holds one 510(k) record, K263582, decided Substantially Equivalent on October 29, 2026, and that single record is also the entire record sample. The same product family was previously cleared under K211385, decided July 27, 2022. Company-level descriptions of Keri Medical come from its own published material, which identifies Medartis as sole shareholder since 2025. [1][2][3][5][8]
The KeriFlex device family and its cleared scope
The KeriFlex® MCP and KeriFlex® PIP Finger Joint Prostheses are indicated for cementless replacement of the metacarpophalangeal and interphalangeal joints, respectively, where those joints are disabled by rheumatoid, degenerative or traumatic arthritis. The K211385 summary describes a sizer with 12 sizes, split into five implants for the interphalangeal (PIP) joint and seven for the metacarpophalangeal (MCP) joint, supplied sterile by plasma gas or ETO, single-use, with a five-year shelf life. Performance testing listed in that summary covers fatigue testing, material characterization and range of motion. [2][3]
The K211385 summary states that the subject and predicate devices share the same intended use, similar technological characteristics and geometries, and similar materials, and that the submitted data demonstrated substantial equivalence. FDA's premarket notification record for K211385 lists the device classification as Prosthesis, Finger, Constrained, Polymer, with an orthopedic review panel, a Traditional submission type, no third-party review and no combination product status. [3][5]
Dated U.S. regulatory record
K211385 was received on May 4, 2021, and decided on July 27, 2022, as Substantially Equivalent. The FDA letter for that submission is addressed to Bernard Prandi as President at Route des Acacias, 45a, Geneva, and names the trade device as KeriFlex® MCP and PIP Finger Joint Prostheses under regulation number 21 CFR 888.3230, Class II, product code KYJ. [3][5]
K263582 was received on September 30, 2026, and decided on October 29, 2026, with decision code SESE, described as Substantially Equivalent, and a clearance type recorded as Special. The filing lists the applicant as Keri Medical SA at Chemin Du Pré-Fleuri, 5, Plan-Les-Ouates, CH 1228, with Camille Miletto as contact, product code KYJ, orthopedic advisory committee, no third-party review, and a summary rather than a statement. The supplied collection contains one 510(k) record with a SESE decision, and the record sample contains that same single entry; these counts describe the supplied filings only and are not measures of total portfolio, sales or safety performance. [1][9]
Applicant identity and corporate context
FDA records identify Keri Medical SA as the applicant, and the addresses appearing in filings are filing addresses rather than a verified headquarters. Keri Medical's own published media kit states that the company was founded in 2016 by Bernard Prandi and Dougal Bendjaballah, that it focuses on hand and wrist orthopedics, and that Medartis has been its sole shareholder since 2025. The same kit lists Medartis Inc. in Warsaw, Indiana, as a U.S. contact point. [1][3][8]
Keri Medical's website describes its mission as supporting healthcare professionals with medical solutions, specialized training and ongoing research, and presents a product range that includes the TOUCH® CMC implant alongside joint implants. The site identifies Keri Medical SA's headquarter address as Chemin du Pré-Fleuri 5, 1228 Plan-les-Ouates, and lists a French entity, Keri Medical France, in Archamps. These company descriptions are attributed to Keri Medical's own publications. [6][7]
